In Vivo Screening Data Summary

NCI In Vivo Screening Data

HT29;CX-1 Human Adenocarcinoma (MER+) (subcutaneous) in NU/NU Swiss (nude) mice

NSC 119875
CAS 15663-27-1
Cisplatin; Plantinol AQ; Cis-DDP

Chemical Data
Schedule (route) Endpoint Vehicle Dose Treated/Control (%) Observations
Q04DX003 (ip) optimum tumor weight change saline 2.0 mg/kg/injection 66.0 Antitumor endpoint evaluated on day 40; 05/05 animals surviving on day 40
Q04DX003 (ip) optimum tumor weight change saline 4.0 mg/kg/injection 78.0 Antitumor endpoint evaluated on day 40; 05/05 animals surviving on day 40
Q04DX003 (ip) optimum tumor weight change saline 8.0 mg/kg/injection 0.0 Antitumor endpoint evaluated on day 40; 02/05 animals surviving on day 40
Q04DX003 (ip) optimum tumor weight change suspension in saline 1.0 mg/kg/injection 67.0 Antitumor endpoint evaluated on day 39; 05/05 animals surviving on day 39
Q04DX003 (ip) optimum tumor weight change suspension in saline 2.0 mg/kg/injection 58.0 Antitumor endpoint evaluated on day 39; 05/05 animals surviving on day 39
Q04DX003 (ip) optimum tumor weight change suspension in saline 4.0 mg/kg/injection 24.0 Antitumor endpoint evaluated on day 39; 04/05 animals surviving on day 39
Q04DX003 (ip) optimum tumor weight change suspension in saline 8.0 mg/kg/injection 0.0 Antitumor endpoint evaluated on day 39; 01/05 animals surviving on day 39